Trials / Terminated
TerminatedNCT01313273
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.
Detailed description
LHRH-a=Luteinizing Hormone-Releasing Hormone Analogues
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanreotide, non steroidal anti androgens and LHRH-a | Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months. Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression. |
| DRUG | Non steroidal anti androgens and LHRH-a | Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-03-11
- Last updated
- 2019-11-22
- Results posted
- 2015-08-14
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01313273. Inclusion in this directory is not an endorsement.